GlobeNewsWire
11 Feb 2026, 23:27 UTC · 40w ago
High Survival Rates With Ryoncil® in EIND Program Emphasize Importance of Earlier Use in Both Children and Adults With SR-aGvHD
Impact · against what's priced in
Mesoblast is initiating a pivotal trial for Ryoncil in adults, potentially tripling its addressable market. Early EIND data showing adult survival rates are at least as favorable as children's reduces the clinical risk of this extension, though efficacy remains highly dependent on early administration.
- MSB+0.70
No priced-in read yet





